iCardiac completes Series B funding

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

iCardiac Technologies has completed a Series B funding round to support further research into a personalized cardiac safety system, developed to assess cardiac risk associated with a range of on-market and in-development drugs.

Advantage Capital Partners, Stonehenge Growth Capital, Trillium Group and other investors, all provided an undisclosed amount of funding for the initiative.

The Rochester, N.Y.-based iCardiac did not disclose the financial terms of the second round of its venture capital.